Literature DB >> 25027401

Secreted protein acidic and rich in cysteine inhibits the growth of human pancreatic cancer cells with G1 arrest induction.

Zhengfa Mao1, Xiaoyan Ma, Xin Fan, Lei Cui, Ting Zhu, Jianguo Qu, Jianxin Zhang, Xuqing Wang.   

Abstract

Aberrant secreted protein acidic and rich in cysteine (SPARC) expression has been reported to play an important role in the tumor development. However, the pattern and the role of SPARC in pancreatic cancer remain largely unknown. Therefore, we further deciphered the role of SPARC played in pancreatic cancer. We first evaluated the SPARC expression in human pancreatic cancer tissues and pancreatic cancer cells. Then we forced expression and silenced SPARC expression in pancreatic cancer cell lines MIA PaCa2 and PANC-1, respectively, using lentivirus vectors. We characterized the stable cells in vitro. In this study, we found that SPARC expression was weak in cancer cells in specimens which negatively correlated with the expression level of phosphorylated pRB and poorer outcome. Moreover, our results demonstrated that SPARC negatively regulated pancreatic cell growth in vitro. Furthermore, we disclosed that the activation of p53 and p27(Kip1) may involve in the effect of SPARC on pancreatic cancer cells. SPARC is downregulated in pancreatic cancer cells and retards the growth of pancreatic cancer cell. Taken together, these results indicate SPARC may be a potential target for pancreatic cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25027401     DOI: 10.1007/s13277-014-2315-0

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  24 in total

1.  Osteonectin influences growth and invasion of pancreatic cancer cells.

Authors:  Ahmed Guweidhi; Jörg Kleeff; Hassan Adwan; Nathalia A Giese; Moritz N Wente; Thomas Giese; Markus W Büchler; Martin R Berger; Helmut Friess
Journal:  Ann Surg       Date:  2005-08       Impact factor: 12.969

2.  SPARC (osteonectin) in breast tumors of different histologic types and its role in the outcome of invasive ductal carcinoma.

Authors:  Yi-Hsuan Hsiao; Huang-Chun Lien; Hsiao-Lin Hwa; Wen-Hung Kuo; King-Jen Chang; Fon-Jou Hsieh
Journal:  Breast J       Date:  2010-02-23       Impact factor: 2.431

Review 3.  The biology of SPARC, a protein that modulates cell-matrix interactions.

Authors:  T F Lane; E H Sage
Journal:  FASEB J       Date:  1994-02       Impact factor: 5.191

4.  Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM.

Authors:  Rolf A Brekken; Pauli Puolakkainen; David C Graves; Gail Workman; Sharon R Lubkin; E Helene Sage
Journal:  J Clin Invest       Date:  2003-02       Impact factor: 14.808

5.  p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21.

Authors:  H Toyoshima; T Hunter
Journal:  Cell       Date:  1994-07-15       Impact factor: 41.582

6.  Overexpression of SPARC obliterates the in vivo tumorigenicity of human hepatocellular carcinoma cells.

Authors:  Catalina Atorrasagasti; Mariana Malvicini; Jorge B Aquino; Laura Alaniz; Mariana Garcia; Marcela Bolontrade; Manglio Rizzo; Osvaldo L Podhajcer; Guillermo Mazzolini
Journal:  Int J Cancer       Date:  2010-06-01       Impact factor: 7.396

7.  Connective tissue growth factor is overexpressed in esophageal squamous cell carcinoma and promotes tumorigenicity through beta-catenin-T-cell factor/Lef signaling.

Authors:  Yue-Zhen Deng; Ping-Ping Chen; Yan Wang; Dong Yin; H Phillip Koeffler; Baojie Li; Xiang-Jun Tong; Dong Xie
Journal:  J Biol Chem       Date:  2007-10-21       Impact factor: 5.157

8.  The Caenorhabditis elegans homologue of the extracellular calcium binding protein SPARC/osteonectin affects nematode body morphology and mobility.

Authors:  J E Schwarzbauer; C S Spencer
Journal:  Mol Biol Cell       Date:  1993-09       Impact factor: 4.138

9.  Cyr61/CCN1 is a tumor suppressor in human hepatocellular carcinoma and involved in DNA damage response.

Authors:  Ping Feng; Bei Wang; Ee Chee Ren
Journal:  Int J Biochem Cell Biol       Date:  2007-07-26       Impact factor: 5.085

10.  SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2'deoxycytidine to increase SPARC expression and improve therapy response.

Authors:  S Cheetham; M J Tang; F Mesak; H Kennecke; D Owen; I T Tai
Journal:  Br J Cancer       Date:  2008-05-06       Impact factor: 7.640

View more
  6 in total

1.  Secreted protein acidic and rich in cysteine enhances the chemosensitivity of pancreatic cancer cells to gemcitabine.

Authors:  Xin Fan; Zhengfa Mao; Xiaoyan Ma; Lei Cui; Jianguo Qu; Lihui Lv; ShengChun Dang; Xuqing Wang; Jianxin Zhang
Journal:  Tumour Biol       Date:  2015-09-10

Review 2.  Do anti-stroma therapies improve extrinsic resistance to increase the efficacy of gemcitabine in pancreatic cancer?

Authors:  Chen Liang; Si Shi; Qingcai Meng; Dingkong Liang; Shunrong Ji; Bo Zhang; Yi Qin; Jin Xu; Quanxing Ni; Xianjun Yu
Journal:  Cell Mol Life Sci       Date:  2017-10-09       Impact factor: 9.261

3.  SPARC promotes pancreatic cancer cell proliferation and migration through autocrine secretion into the extracellular milieu.

Authors:  Kehua Pan; Xince Huang; Xiufen Jia
Journal:  Oncol Lett       Date:  2021-04-21       Impact factor: 2.967

Review 4.  Prognostic Value of SPARC in Patients with Pancreatic Cancer: A Systematic Review and Meta-Analysis.

Authors:  Wei Han; Fang Cao; Min-bin Chen; Rong-zhu Lu; Hua-bing Wang; Min Yu; Chun-tao Shi; Hou-zhong Ding
Journal:  PLoS One       Date:  2016-01-05       Impact factor: 3.240

5.  Osteonectin as a screening marker for pancreatic cancer: A prospective study.

Authors:  Angeliki Papapanagiotou; George Sgourakis; Kyriakos Karkoulias; Dimitris Raptis; Edward Parkin; Pantelis Brotzakis; Sanjay Panchal; Athanasios G Papavassiliou
Journal:  J Int Med Res       Date:  2018-05-13       Impact factor: 1.671

6.  An Attempt to Evaluate Selected Aspects of "Bone-Fat Axis" Function in Healthy Individuals and Patients With Pancreatic Cancer.

Authors:  Wojciech Blogowski; Katarzyna Dolegowska; Anna Deskur; Barbara Dolegowska; Teresa Starzyńska
Journal:  Medicine (Baltimore)       Date:  2015-08       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.